Can a lung drug stop COVID scarring?

NCT ID NCT04619680

Completed Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether nintedanib, a drug used for other lung diseases, can slow down lung damage in people who had severe COVID-19. It included 103 adults who still had lung problems more than 30 days after their COVID diagnosis. The main goal was to see if the drug helped maintain lung function over 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 Fibrosis interstitial lung disease pulmonary fibrosis Respiration Disorders respiratory system disorder severe cutaneous adverse reaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE PULMONARY FIBROSIS RESPIRATORY DISEASE

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Baylor University Medical Center Dallas

Dallas, Texas, 75246, United States
Emory Healthcare Network

Atlanta, Georgia, 30322, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Mount Sinai Beth Israel

New York, New York, 10003, United States
The Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States
University of Utah

Salt Lake City, Utah, 84108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.